NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
312 trialsNCT06803680 2026-04-15
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT01642017 2026-04-14
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT05372614 2026-04-14
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT03030378 2026-04-13
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04585958 2026-04-13
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687110 2026-04-13
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-04-13
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-04-13
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06223542 2026-04-13
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06606990 2026-04-13
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07524140 2026-04-13
Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.
Eilean Therapeutics
Phase 1 Not yet recruiting
NCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT07144085 2026-04-03
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
First Hospital of China Medical University
Phase 1 Recruiting
NCT04050709 2026-04-01
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
Phase 1 Completed
NCT02133625 2026-03-30
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04419532 2026-03-20
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05720117 2026-03-20
A Study of PYX-201 in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1 Recruiting
NCT06911008 2026-03-19
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
Phase 1 Recruiting
NCT07403721 2026-03-19
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT07454031 2026-03-13
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
Phase 1 Not yet recruiting
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT07197671 2026-03-12
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT07269080 2026-03-02
STM-06
University of Illinois at Chicago
Phase 1 Recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06389123 2026-02-27
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
University of California, Davis
Phase 1 Recruiting
NCT06521554 2026-02-25
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
Phase 1 Recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT00923806 2026-01-23
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05914545 2026-01-22
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07348107 2026-01-16
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT04471987 2026-01-14
DODEKA
Philogen S.p.A.
Phase 1 Recruiting
NCT03065387 2026-01-12
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06235437 2026-01-07
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT02560636 2026-01-06
PLUMMB
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT06337630 2026-01-02
POP-ART
Institut Curie
Phase 1 Terminated
NCT04621435 2025-12-31
Imaging of Solid Tumors Using FAP-2286
University of California, San Francisco
Phase 1 Recruiting